Glecaprevir/Pibrentasvir Real-world Study in China

Tongji Hospital

Status: Unknown

Conditions: Chronic Hepatitis c

Treatments: Drug: Glecaprevir/Pibrentasvir

Study type: Observational

Funder types: Other

Identifiers

NCT03941821

G/P RWS China

Details and patient eligibility

About

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

Full description

This study is a multi-center, prospective, real-world study, aiming to investigate the use of Glecaprevir/Pibrentasvir in routine clinical management of chronic hepatitis C patients and evaluate its effectiveness and safety across a heterogeneous population in China.Approximately 800 patients will take part in this study, 20 sites will be included which distribute in China's major cities, thus each site will enroll 40 patients.

Enrollment: 800 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• >18 years old
• Meet the standard of Glecaprevir/Pibrentasvir treatment

Exclusion criteria

• Patients have contraindications to Glecaprevir/Pibrentasvir
• Pregnancy or lactation
• Malignancy
• Decompensatory cirrhosis

Trial design

800 participants in 1 patient group

G/P treatment

Description:

Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment

Treatment:

Drug: Glecaprevir/Pibrentasvir